Patents by Inventor Lung C. Chen

Lung C. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anhydroecogonine compounds and their use as anticholinergic agents
    Patent number: 5821249
    Abstract: Methylecgonidine (MEG; anhydroecgonine methylester), is produced when cocaine base ("crack") is heated. MEG alone and in combination with cocaine was tested for action on isolated tracheal rings stimulated to contact with acetylcholine. At micromolar concentrations, cocaine sensitized tracheal rings, increasing both the potency and efficacy of acetylcholine-induced contraction. Surprisingly, MEG, at nanomolar concentrations and above, non-competitively and irreversibly antagonized acetylcholine-induced contraction independently of the actions of cocaine. MEG also displayed antihistaminic activity. Therefore, MEG and anticholinergically active derivatives or analogues thereof are useful in the prevention or treatment of a disease or disorder treatable by an antimuscarinic anticholinergic agent, an anti-histaminic agent or a spasmolytic agent, in particular bronchoconstriction in a number of pulmonary diseases such as asthma.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: October 13, 1998
    Assignee: University of Rochester
    Inventors: Ronald W. Wood, Hassan A. N. El-Fawal, John F. Graefe, Lung C. Chen, Jalil Shojaie
  • Anhydroecgonine compounds and their use as anticholinergic agents
    Patent number: 5552407
    Abstract: Methylecgonidine (MEG; anhydroecgonine methylester), is produced when cocaine base ("crack") is heated. MEG alone and in combination with cocaine was tested for action on isolated tracheal rings stimulated to contact with acetylcholine. At micromolar concentrations, cocaine sensitized tracheal rings, increasing both the potency and efficacy of acetylcholine-induced contraction. Surprisingly, MEG, at nanomolar concentrations and above, non-competitively and irreversibly antagonized acetylcholine-induced contraction independently of the actions of cocaine. MEG also displayed antihistaminic activity. Therefore, MEG and anticholinergically active derivatives or analogues thereof are useful in the prevention or treatment of a disease or disorder treatable by an antimuscarinic anticholinergic agent, an anti-histaminic agent or a spasmolytic agent, in particular bronchoconstriction in a number of pulmonary diseases such as asthma.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: September 3, 1996
    Assignee: New York University Medical Center
    Inventors: Ronald W. Wood, Hassan A. N. El-Fawal, John F. Graefe, Lung C. Chen, Jalil Shojaie